GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS) for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply ...

SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the activation of two additional clinical trial sites for its ongoing Phase 1/2a trial evaluating troculeucel, cryopreserved expanded autologous NK cell therapy, in patients with moderate Alzheimer’s disease (“AD”) ...

Company has applied for new Commissioner's National Priority Vouchers (CNPV) for NRX-100. Continues to anticipate decisions on drug approval by year-end 2025 Application under CNPV program is accretive to already-filed Abbreviated New Drug Application (ANDA) for preservative-free ketamine, with proprietary formulation under priority review request Company has received and complied with FDA information request for updated drug ingredient and label information on NRX-100 Company has previously filed full Che ...

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare® Pharmacy to select telehealth organizations that share our commitment to safe and effective ...

WILMINGTON, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (TSXV: SCAN, OTCQB: LDDFF, FSE: E30), a leading technology provider of AI-based next generation detection solutions for concealed weapons and threats, is pleased to announce that its HEXWAVE system successfully demonstrated a comprehensive detection capability for concealed metallic and non-metallic threats with minimal false alarms for deployment at courthouses and correctional facilities. HEXWAV ...

The funding will specifically enable Special Olympics to grow and scale the delivery of their workforce readiness trainings, Athlete Leadership programming, and Unified Leadership, a training co-developed and facilitated by people with IDD that is designed to develop inclusive mindsets to facilitate a more accepting and inclusive workplace for people of all abilities. To date, the training has been offered to more than 2,000 businesses, schools, and community organizations around the world. "Bank of America ...

Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral ...

A Strategic Move to Accelerate Market Reach for Innovative Pharmaceutical Patents on June 23, 2025 NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Dr Ashleys Limited, a Hong Kong based global pharmaceutical company (“Dr Ashleys”), and Impact BioMedical Inc. (“Impact BioMedical”) (NYSE American: IBO), a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American (“Impact BioMedical”, together with Dr Ashleys, the “Parties”), are pleased to announce the execution of a merger and share ...

Group 1 - The core focus is on the increased investment by Sylebra, a hedge fund, in Aeva, a lidar technology company, during its SPAC phase, indicating growing confidence in the company's prospects [1] - The analysis highlights a shift in interest from solar manufacturers and renewable yieldcos to lidar companies, emphasizing the importance of technology, adoption rates, and revenue growth in this sector [1]

Company Overview - Granite Ridge Resources, Inc. (GRNT) shares increased by 6.7% to close at $6.41, supported by higher trading volume compared to normal sessions [1] - The company is positioned to benefit from rising oil prices due to geopolitical tensions, particularly the conflict between Israel and Iran, which has led to a 13% increase in Brent crude and a 10% increase in West Texas Intermediate (WTI) [2] Financial Performance - Granite Ridge is expected to report quarterly earnings of $0.17 per share, reflecting a year-over-year increase of 30.8%, with revenues projected at $111 million, up 22.5% from the previous year [3] - The consensus EPS estimate for Granite Ridge has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Market Position - The company operates as a non-operated oil and natural gas exploration and production entity with a diverse portfolio across major U.S. basins, which enhances its operational flexibility and attractiveness in a volatile market [2] - Granite Ridge holds a Zacks Rank of 3 (Hold), indicating a neutral outlook in the current market context [5]